Mandate

Vinge advises on equity line and rights issue guarantee to Karo Bio

October 27, 2010

Azimuth Opportunity, Inc and Karo Bio AB (publ) (NASDAQ OMX Stockholm) have entered an agreement regarding a so-called Equity Credit Facility, whereby Azimuth has undertaken to subscribe for new shares in Karo Bio on Karo Bio’s request and as set out in the terms of the facility, of up to USD 35 million. In addition, Azimuth guarantees part of Karo Bio’s rights issue of approx. SEK 300 million. The Facility and the rights issue are subject to approval by the general meeting of Karo Bio.

Vinge advises Azimuth. Vinge’s team is headed by capital markets partner Erik Sjöman.

Related

Vinge has advised Investor in connection with acquisition of shares in EQT

Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026